Could low muscle mass predict nerve pain from chemo?

NCT ID NCT06996548

Completed Knowledge-focused Sponsor: Gazi University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 120 women with early-stage breast cancer to see if having low muscle mass (sarcopenia) before treatment raises the risk of nerve damage from the chemotherapy drug paclitaxel. Researchers measured muscle mass on CT scans and checked for nerve symptoms using questionnaires and nerve tests. The goal was to find out if muscle loss can help predict who might get nerve problems from chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm chemotherapy-induced neuropathy Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA PACLITAXEL INDUCED NEUROPATHY SARCOPENIA

Contacts and locations

Locations

Ankara Etlik City Hospital

Ankara, Yenimahalle, 06170, Turkey (Türkiye)
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Ankara, Yenimahalle, 06200, Turkey (Türkiye)
Gazi University

Ankara, Yenimahalle, 06560, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.